Ottawa, ON /Business Wire/ November 13, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”   or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune   function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants   exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants currently have an expiration date of November 30, 2020. Subject to TSX Venture Exchange approval, the new date of expiry for such warrants will be June 30, 2021. All other terms of such warrants will remain unchanged.          

About Avivagen  
Avivagen is a life sciences corporation focused on developing and commercializing products for   livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby   promoting general health and performance in animals.  Avivagen is a public corporation traded on the   TSX Venture and OTCQB® Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of   Canada and Charlottetown, Prince Edward Island. For more information, visit The contents of the website are expressly not incorporated by reference in this press release.              

About OxC-beta™ Technology and OxC-beta™ Livestock  
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other   carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of   immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-  beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the   antibiotics commonly added to livestock feeds. The product is currently available for sale in the United   States, Philippines, Taiwan, New Zealand, Thailand, Australia, Malaysia, Mexico & Brazil.          

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove   all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and   swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in   some aspects, better than in-feed antibiotics.          

Forward Looking Statements  
This news release includes certain forward-looking statements that are based upon the current   expectations of management. Forward-looking statements involve risks and uncertainties associated  with the business of Avivagen Inc. and the environment in which the business operates. Any statements   contained herein that are not statements of historical facts may be deemed to be forward-looking,   including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”,   “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”,   “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions.   Statements set out in this news release relating to the possibility for OxC-beta™ Livestock to replace   antibiotics in livestock feeds as growth promoters and the proposed warrant extension are forward-  looking statements. These forward-looking statements are subject to a number of risks and uncertainties   that could cause actual results or events to differ materially from current expectations. For instance,   Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for   new applications and may not be widely accepted as a replacement for antibiotics as growth promoters   in livestock feeds due to many factors, many of which are outside of Avivagen’s control. The warrant   extension is conditional on TSX Venture Exchange approval and the agreement of Computershare Trust   Company of Canada which acts as Warrant Agent for such warrants, both of which are outside of   Avivagen’s control.  Readers are referred to the risk factors associated with the business of Avivagen set   out in Avivagen’s most recent management’s discussion and analysis of financial condition available at Except as required by law, Avivagen assumes no obligation to update the forward-  looking statements, or to update the reasons why actual results could differ from those reflected in the   forward-looking statements.          

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies   of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

For more information:  
Avivagen Inc.  
Drew Basek  
Director of Investor Relations  
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6  
Phone: 416-540-0733  

Kym Anthony  
Chief Executive Officer  
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head   Office Phone: 613-949-8164  
Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.